Firstly hospitals are big places, and if Sphygmocor becomes a standard tool they're likely to buy more than one each.
Secondly the key to growth is not just in hospitals but in private practice, and there are a lot of those. If you look at the Oct 14 presentation they're anticipating of order $20-50 reimbursement per measurement. Now while the arguments for Sphygmocor may be based on sound medical practice (800 peer reviewed publications blah blah blah) the simple fact is that the units will be a gravy train for practitioners. While that probably tells you what's wrong with the US medical system, it's good for the company.
The risk is that other market entrants take a slice of the pie- and that's a big risk, now that the technology has Cat 1 there's an incentive for other players to come in and rip off the technology. The mitigation is that ACG has the technology dominant in the research sector and that should trickle down to the primary care market (because doctors read journal articles. Allegedly).
The dream is that this is a technology that becomes routine and ubiquitous in the treatment for a range of illnesses. With a population of 300 million, I think total sales of 100,000 are not out of the question and sales of over 10000 I would regard as the absolute minimum.
Nothing is certain otherwise the SP would be ten bucks, but the market is far larger than 5000 units.
Add to My Watchlist
What is My Watchlist?
